858 related articles for article (PubMed ID: 19344246)
1. Hepatitis C virus virology and new treatment targets.
Meier V; Ramadori G
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
[TBL] [Abstract][Full Text] [Related]
2. Novel hepatitis C drugs in current trials.
Kronenberger B; Welsch C; Forestier N; Zeuzem S
Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
[TBL] [Abstract][Full Text] [Related]
3. Future directions in therapy for chronic hepatitis C.
Jensen DM; Ascione A
Antivir Ther; 2008; 13 Suppl 1():31-6. PubMed ID: 18432161
[TBL] [Abstract][Full Text] [Related]
4. Serine protease inhibitors as anti-hepatitis C virus agents.
Reiser M; Timm J
Expert Rev Anti Infect Ther; 2009 Jun; 7(5):537-47. PubMed ID: 19485794
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibitors of hepatitis C virus replication.
Neyts J
Antiviral Res; 2006 Sep; 71(2-3):363-71. PubMed ID: 16843538
[TBL] [Abstract][Full Text] [Related]
6. Future therapies for hepatitis C.
Pawlotsky JM; Gish RG
Antivir Ther; 2006; 11(4):397-408. PubMed ID: 16856613
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
Cristina J; del Pilar Moreno M; Moratorio G
Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
[TBL] [Abstract][Full Text] [Related]
8. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and clinical aspects on hepatitis C.
Higuchi M; Tanaka E; Kiyosawa K
Jpn J Infect Dis; 2002 Jun; 55(3):69-77. PubMed ID: 12195046
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus infection in haemodialysis and kidney transplant patients.
Baid-Agrawal S; Pascual M; Moradpour D; Frei U; Tolkoff-Rubin N
Rev Med Virol; 2008; 18(2):97-115. PubMed ID: 18064722
[TBL] [Abstract][Full Text] [Related]
11. Non-nucleoside inhibitors of the HCV polymerase.
Sarisky RT
J Antimicrob Chemother; 2004 Jul; 54(1):14-6. PubMed ID: 15190019
[TBL] [Abstract][Full Text] [Related]
12. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
[TBL] [Abstract][Full Text] [Related]
13. Present and future therapy for hepatitis C virus.
Cornberg M; Deterding K; Manns MP
Expert Rev Anti Infect Ther; 2006 Oct; 4(5):781-93. PubMed ID: 17140355
[TBL] [Abstract][Full Text] [Related]
14. Treatment choices for people infected with HCV.
Fargion S; Fracanzani AL; Valenti L
J Antimicrob Chemother; 2004 May; 53(5):708-12. PubMed ID: 15073158
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus: prospects for future therapies.
Wilkinson T
Curr Opin Investig Drugs; 2001 Nov; 2(11):1516-22. PubMed ID: 11763151
[TBL] [Abstract][Full Text] [Related]
17. Existing and future therapeutic options for hepatitis C virus infection.
Bretner M
Acta Biochim Pol; 2005; 52(1):57-70. PubMed ID: 15827606
[TBL] [Abstract][Full Text] [Related]
18. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes.
Hnatyszyn HJ
Antivir Ther; 2005; 10(1):1-11. PubMed ID: 15751759
[TBL] [Abstract][Full Text] [Related]
19. Challenges and successes in developing new therapies for hepatitis C.
De Francesco R; Migliaccio G
Nature; 2005 Aug; 436(7053):953-60. PubMed ID: 16107835
[TBL] [Abstract][Full Text] [Related]
20. Evaluation systems for anti-HCV drugs.
Moriishi K; Matsuura Y
Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
